| scholarly article | Q13442814 |
| P2093 | author name string | Shuxing Zhang | |
| A. Srinivas Reddy | |||
| P2860 | cites work | The Protein Data Bank | Q24515306 |
| DrugBank 3.0: a comprehensive resource for 'omics' research on drugs | Q24612505 | ||
| BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities | Q24675698 | ||
| Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action | Q26824166 | ||
| Structure-based virtual screening for drug discovery: a problem-centric review | Q27022502 | ||
| Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases | Q27652488 | ||
| ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
| Network biology: understanding the cell's functional organization | Q27861027 | ||
| Recurrent spontaneous early pregnancy loss and low dose aspirin | Q28165837 | ||
| Aspirin non-responder status in patients with recurrent cerebral ischemic attacks | Q28194630 | ||
| Dosing frequency of aspirin and prevention of heart attacks and strokes | Q28221854 | ||
| Drug discovery: Predicting promiscuity | Q28264510 | ||
| Text mining for the biocuration workflow | Q28264766 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| Navigating chemical space for biology and medicine | Q28298611 | ||
| ChEMBL: a large-scale bioactivity database for drug discovery | Q28315179 | ||
| STITCH: interaction networks of chemicals and proteins | Q28465606 | ||
| A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology | Q28472464 | ||
| A mapping of drug space from the viewpoint of small molecule metabolism | Q28475993 | ||
| Prediction of chemical-protein interactions network with weighted network-based inference method | Q28481329 | ||
| How to link ontologies and protein-protein interactions to literature: text-mining approaches and the BioCreative experience | Q28731022 | ||
| Text mining and manual curation of chemical-gene-disease networks for the comparative toxicogenomics database (CTD) | Q28750346 | ||
| JChem: Java Applets and Modules Supporting Chemical Database Handling from Web Browsers | Q28837141 | ||
| Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs | Q28969532 | ||
| IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data | Q29043128 | ||
| KEGG for integration and interpretation of large-scale molecular data sets | Q29547277 | ||
| The druggable genome | Q29547361 | ||
| Drug-target network | Q29614447 | ||
| Database resources of the National Center for Biotechnology Information | Q29614503 | ||
| Drug target identification using side-effect similarity | Q29615103 | ||
| Global mapping of pharmacological space | Q29615876 | ||
| Relating protein pharmacology by ligand chemistry | Q29617492 | ||
| Ligand Depot: a data warehouse for ligands bound to macromolecules | Q30918637 | ||
| The model organism as a system: integrating 'omics' data sets | Q31032864 | ||
| The Comparative Toxicogenomics Database facilitates identification and understanding of chemical-gene-disease associations: arsenic as a case study. | Q33374871 | ||
| Integrating text mining into the MGI biocuration workflow | Q33554526 | ||
| New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide | Q33826198 | ||
| Drug effect prediction by polypharmacology-based interaction profiling | Q34078333 | ||
| PubChem's BioAssay Database | Q34090643 | ||
| Predicting new molecular targets for rhein using network pharmacology | Q34203691 | ||
| The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. | Q34289660 | ||
| The Comparative Toxicogenomics Database: update 2011. | Q34456573 | ||
| New uses for old drugs | Q34661227 | ||
| An inverse docking approach for identifying new potential anti-cancer targets. | Q34744590 | ||
| Systems approaches to polypharmacology and drug discovery | Q34746314 | ||
| Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. | Q34854658 | ||
| Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing. | Q35694643 | ||
| Key factors in the rising cost of new drug discovery and development | Q35770173 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| Drug Repurposing: Far Beyond New Targets for Old Drugs | Q36331528 | ||
| Binding MOAD, a high-quality protein-ligand database. | Q36454178 | ||
| Inhibition of angiogenesis in the treatment of non-small cell lung cancer | Q36950548 | ||
| Chemical genetic discovery of targets and anti-targets for cancer polypharmacology | Q36988960 | ||
| Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions | Q37091483 | ||
| Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. | Q37283297 | ||
| Docking and chemoinformatic screens for new ligands and targets | Q37592631 | ||
| The role of pemetrexed combined with targeted agents for non-small cell lung cancer | Q37617444 | ||
| Molecular networks in drug discovery. | Q37798843 | ||
| Computational tools for polypharmacology and repurposing | Q37894712 | ||
| Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks | Q38012518 | ||
| Knowledge discovery by automated identification and ranking of implicit relationships | Q38423824 | ||
| SuperTarget goes quantitative: update on drug-target interactions | Q38499993 | ||
| Therapy of symptomatic pericarditis after myocardial infarction: Retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution | Q39567649 | ||
| Systems Pharmacology | Q41862157 | ||
| Cross-pharmacology analysis of G protein-coupled receptors | Q41875668 | ||
| Knockouts model the 100 best-selling drugs--will they model the next 100? | Q43436501 | ||
| Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule | Q43558049 | ||
| Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. | Q44722485 | ||
| Exploring polypharmacology using a ROCS-based target fishing approach | Q45783965 | ||
| Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. | Q45908190 | ||
| New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications | Q47861024 | ||
| Functional and topological characterization of protein interaction networks | Q47866212 | ||
| Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases | Q51941401 | ||
| Mapping drug-target interaction networks | Q53807639 | ||
| A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo | Q54526385 | ||
| Network pharmacology | Q57932497 | ||
| New drugs. 8. Flufenamic acid in rheumatoid arthritis. Comparison with aspirin and the results of extended treatment | Q72849189 | ||
| Risks in new drug development: approval success rates for investigational drugs | Q73924789 | ||
| New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer | Q81274554 | ||
| Systems biology: Hypothesis-driven omics integration | Q84433573 | ||
| NCATS launches drug repurposing program | Q84560434 | ||
| Aspirin and Cancer: Trials and Observational Studies | Q84783541 | ||
| Evaluation of various inverse docking schemes in multiple targets identification | Q85237803 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adverse drug reaction | Q45959 |
| drug discovery | Q1418791 | ||
| polypharmacology | Q21823227 | ||
| pharmaceutical databases | Q70331479 | ||
| P304 | page(s) | 41-47 | |
| P577 | publication date | 2013-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Polypharmacology: drug discovery for the future | |
| P478 | volume | 6 |
| Q90401017 | 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication |
| Q36009841 | A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation |
| Q58711062 | A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning |
| Q90040651 | A Multi-Label Learning Framework for Drug Repurposing |
| Q92736060 | A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells |
| Q38740513 | A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response |
| Q28554371 | A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug Effects |
| Q92572724 | A Scalable, Multiplexed Assay for Decoding GPCR-Ligand Interactions with RNA Sequencing |
| Q47213804 | A census of P. longum's phytochemicals and their network pharmacological evaluation for identifying novel drug-like molecules against various diseases, with a special focus on neurological disorders |
| Q28385286 | A generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling |
| Q36290627 | A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids |
| Q38745700 | A workflow for in silico design of hIL-10 and ebvIL-10 inhibitors using well-known miniprotein scaffolds. |
| Q46752829 | AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways |
| Q42645955 | An integrated structure- and system-based framework to identify new targets of metabolites and known drugs. |
| Q38364325 | Anticancer properties of lamellarins |
| Q91843016 | Antidepressants are modifiers of lipid bilayer properties |
| Q38770314 | Autophagy as a target for therapeutic uses of multifunctional peptides. |
| Q62494154 | Binding site matching in rational drug design: algorithms and applications |
| Q38243624 | Biological networks and drug discovery--where do we stand? |
| Q59808648 | Cannabinoids and Pain: New Insights From Old Molecules |
| Q92636043 | Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy |
| Q35206344 | Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. |
| Q47096038 | Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs |
| Q35825358 | Chemical genetics and regeneration |
| Q39609944 | Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. |
| Q33944326 | Composition and applications of focus libraries to phenotypic assays |
| Q27902291 | Creation of a free, Internet-accessible database: the Multiple Target Ligand Database |
| Q34222917 | Curation and analysis of multitargeting agents for polypharmacological modeling |
| Q48231458 | DESIGNER Extracts as Tools to Balance Estrogenic and Chemopreventive Activities of Botanicals for Women's Health. |
| Q28387804 | Discovery and development of natural product oridonin-inspired anticancer agents |
| Q89578223 | Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents |
| Q63246314 | Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy |
| Q26748728 | Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders |
| Q39060517 | Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis |
| Q42333457 | Editorial: Computational and Experimental Approaches in Multi-target Pharmacology |
| Q38663728 | Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited |
| Q64889053 | Exploring African Medicinal Plants for Potential Anti-Diabetic Compounds with the DIA-DB Inverse Virtual Screening Web Server. |
| Q64886116 | Exploring the Potential of Spherical Harmonics and PCVM for Compounds Activity Prediction. |
| Q47769226 | Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology. |
| Q57976104 | FD5180, a Novel Protein Kinase Affinity Probe, and the Effect of Bead Loading on Protein Kinase Identification |
| Q39184034 | Future De Novo Drug Design |
| Q34389708 | GPCRDB: an information system for G protein-coupled receptors |
| Q47714123 | Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase |
| Q27902303 | Improving chemical similarity ensemble approach in target prediction |
| Q47323180 | Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery |
| Q48595586 | In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells |
| Q38465124 | In silico tools used for compound selection during target-based drug discovery and development |
| Q31041986 | Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data |
| Q90383613 | LigBuilder V3: A Multi-Target de novo Drug Design Approach |
| Q50212515 | MTLD, a Database of Multiple Target Ligands, the Updated Version |
| Q37535523 | Modulation of cyclins, p53 and mitogen-activated protein kinases signaling in breast cancer cell lines by 4-(3,4,5-trimethoxyphenoxy)benzoic acid |
| Q39120175 | Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A. |
| Q55286943 | Multi-target drug repositioning by bipartite block-wise sparse multi-task learning. |
| Q38647687 | Multiple target-centric strategy to tame inflammation |
| Q90192897 | Multitarget Approaches against Multiresistant Superbugs |
| Q42230712 | Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015 |
| Q61814456 | Network-Based Assessment of Adverse Drug Reaction Risk in Polypharmacy Using High-Throughput Screening Data |
| Q92860441 | Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors |
| Q64268861 | Novel Approach for the Search for Chemical Scaffolds with Dual Activity with Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor-A Perspective for the Treatment of Neurodegenerative Disorders |
| Q38233063 | Novel approaches to drug discovery for the treatment of type 2 diabetes |
| Q35874098 | One size does not fit all: Challenging some dogmas and taboos in drug discovery. |
| Q52610098 | Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain |
| Q92043306 | Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety |
| Q51347974 | Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120). |
| Q38827815 | Polypharmacology in Drug Development: A Minireview of Current Technologies. |
| Q58566984 | Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets |
| Q64885983 | Privileged Structures and Polypharmacology within and between Protein Families. |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q26739684 | Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting |
| Q47592781 | Quality of life and treatment satisfaction observed among Indians with diabetes foot ulcers undergoing ayurvedic adjunct therapy |
| Q96690650 | Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2 |
| Q90478765 | Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment |
| Q38755043 | Resisting resistance: is there a solution for malaria? |
| Q38661320 | Rosmarinic Acid Protects against Inflammation and Cardiomyocyte Apoptosis during Myocardial Ischemia/Reperfusion Injury by Activating Peroxisome Proliferator-Activated Receptor Gamma |
| Q92209179 | Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors |
| Q89207719 | Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs |
| Q47290719 | Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. |
| Q38723513 | Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors |
| Q28822412 | Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine |
| Q35777950 | Systematic synergy modeling: understanding drug synergy from a systems biology perspective |
| Q36087088 | Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders |
| Q35552376 | Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting |
| Q28553277 | The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective |
| Q39157903 | The Isoxazole Ring and Its N-Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics |
| Q39507246 | The allelochemical MDCA inhibits lignification and affects auxin homeostasis |
| Q38934855 | The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors |
| Q52590407 | Therapeutic potential of multifunctional tacrine analogues. |
| Q61815073 | Tocotrienols Modulate a Life or Death Decision in Cancers |
| Q38256258 | Tools for in silico target fishing |
| Q39166795 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I. |
| Q57171032 | Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations |
| Q35889533 | Virtual Screening and Experimental Validation Identify Novel Inhibitors of the Plasmodium falciparum Atg8-Atg3 Protein-Protein Interaction. |
Search more.